Kymera Therapeutics KYMR Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kymera Therapeutics's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kymera Therapeutics's financing cash flow?
- Kymera Therapeutics (KYMR) reported financing cash flow of $18.77M in Q1 2026.
- How has Kymera Therapeutics's financing cash flow changed year-over-year?
- Kymera Therapeutics's financing cash flow increased by 7174.8% year-over-year, from $258K to $18.77M.
- What is the long-term trend for Kymera Therapeutics's financing cash flow?
- Over 4 years (2021 to 2025), Kymera Therapeutics's financing cash flow has grown at a 41.1% compound annual growth rate (CAGR), from $250.28M to $990.71M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.